Drug name(s)
Inqovi® Decitabine and cedazuridineIndications and usage
Inqovi is FDA approved:
- For treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate1, intermediate-2, and high-risk International Prognostic Scoring System groups.
- In combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Side effects needing medical attention
In MDS or CMML, the most common adverse reactions are fatigue, constipation, hemorrhage, muscle pain or aches, mucositis, joint stiffness, nausea, shortness of breath, diarrhea, rash, dizziness, febrile neutropenia, swelling caused by fluid trapped in body tissues, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, and transaminase increased. The most common lab abnormalities were leukocytes decreased, platelet count decreased, neutrophil count decreased, and hemoglobin decreased.
In AML in combination with venetoclax, the most common adverse reactions are neutropenia, febrile neutropenia, thrombocytopenia, hemorrhage, anemia, infection (bacterial/viral), diarrhea, fatigue, mucositis, constipation, joint stiffness, shortness of breath, decreased appetite, swelling caused by fluid trapped in body tissues, nausea, white blood cell count decreased, sepsis, pneumonia, rash, transaminitis, muscle pain or aches, arrhythmia, and abdominal pain. The most common Grade 3 or 4 lab abnormalities were leukocytes decreased, lymphocytes decreased, platelets decreased, and hemoglobin decreased.